Tutschka P J, Beschorner W E, Hess A D, Santos G W
Blood. 1983 Feb;61(2):318-25.
Cyclosporin-A (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for aplastic anemia and hematologic malignancies. The drug was given daily for 180 days starting with the day of marrow infusion. Engraftment was not impaired and myelotoxicity was not observed. Cutaneous graft-versus-host disease (GVHD) developed in five patients and all either spontaneously resolved or promptly responded to therapy with steroids. Five patients developed systemic GVHD and all responded to therapy with steroids, but only two survived. Interstitial pneumonia was seen in six patients and was fatal in all of them. Liver function abnormalities were seen in 14 patients but could not positively be correlated with CsA administration. Renal function abnormalities were seen in 17 patients. Amphotericin-B therapy contributed significantly to the renal failure. Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities. Overall survival so far has been 50.0%. Second malignancies were not observed, but one patient relapsed with leukemia at 343 days.
将环孢素A（CsA）给予22例接受异基因骨髓移植治疗再生障碍性贫血和血液系统恶性肿瘤的患者。从骨髓输注当天开始，每日给药，持续180天。植入未受影响，未观察到骨髓毒性。5例患者发生了皮肤移植物抗宿主病（GVHD），所有患者均自发缓解或迅速对类固醇治疗产生反应。5例患者发生了全身性GVHD，所有患者均对类固醇治疗有反应，但仅2例存活。6例患者出现间质性肺炎，全部死亡。14例患者出现肝功能异常，但无法明确与CsA给药相关。17例患者出现肾功能异常。两性霉素B治疗对肾衰竭有显著影响。通过放射免疫测定法测得的CsA血清水平与肝功能或肾功能异常的存在无关。迄今为止，总体生存率为50.0%。未观察到第二原发性恶性肿瘤，但1例患者在343天时白血病复发。
